Nuvation Bio Inc. (NUVB)

Market Cap	1.60B +107.3%
Revenue (ttm)	62.90M +699.0%
Net Income	-204.63M
EPS	-0.60
Shares Out	342.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,049,955
Open	4.450
Previous Close	4.570
Day's Range	4.430 - 4.730
52-Week Range	1.540 - 9.750
Beta	1.51
Analysts	Strong Buy
Price Target	11.22 (+139.74%)
Earnings Date	Mar 2, 2026

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and ext...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 291
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Financial Performance

In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $11.22, which is an increase of 139.74% from the latest price.

Price Target

$11.22

(139.74% upside)

Analyst Consensus: Strong Buy